A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Phase 2
49
about 3.8 years
18+
10 sites in MA, NJ, NY +2
What this study is about
Researchers are testing whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer. The trial will last approximately 1398 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take 5-Fluorouracil
- 2.Take Capecitabine
- 3.Take Docetaxel
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
fluorouracil (Antimetabolite; mimics uracil to disrupt DNA/RNA in cancer cells), capecitabine, docetaxel, oxaliplatin, pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer), trastuzumab (Monoclonal antibody; targets HER2 protein on cancer cells)
oral (Oral Tablet), infusion, injection (Injection), injection, intravenous
Primary: Event-free survival (EFS)